Abstract
Background: The use of long-term central venous catheters (CVCs) could lead to serious bloodstream infections. Removal of the infected CVC and reinsertion of a new CVC are not always feasible and alternative lock therapy may be considered. We conducted a multicenter trial to assess the efficacy and safety of the lock therapy. Methods: Between October 2013 and August 2014, we prospectively enrolled 20 patients with catheter-related bloodstream infections (CRBSIs) or central line-associated bloodstream infections (CLABSIs) in our sister institutions in three countries including Brazil, Lebanon, and Japan. The 20 patients who received M-EDTA-EtOH lock therapy were compared to 24 control patients who had their CVCs removed and a new CVC inserted. Results: Both groups had comparable clinical characteristics. In the lock therapy group, 95% of the patients had microbiological eradication within 96 h after starting lock therapy versus 83% of the patients in the control group (p = .36). In the lock group, the CVC was salvaged and retained for a median of 21 days (range 7–51) from the onset of bacteremia. Conclusion: Our study suggests that M-EDTA-EtOH lock therapy may be an effective intervention to salvage long-term CVCs in the setting of CLABSI/CRBSI and hemodialysis cancer patients with limited vascular access.
Original language | English (US) |
---|---|
Pages (from-to) | 461-466 |
Number of pages | 6 |
Journal | Expert Review of Medical Devices |
Volume | 15 |
Issue number | 6 |
DOIs | |
State | Published - Jun 3 2018 |
Keywords
- EDTA
- bloodstream infections
- central catheters
- central line associated
- ethanol lock
- minocycline
ASJC Scopus subject areas
- Surgery
- Biomedical Engineering